AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04011007 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vitrectomy with or without inverted ILM flap technique
Description: vitrectomy without ILM peeling versus vitrectomy with inverted ILM flap technique in cases of macular hole retinal detachment in high myopic eyes.
Study NCT01049438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nasal mupirocin
Description: twice daily for 10 days
Study NCT01049438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical 3% hexachlorophene body wash
Description: daily for 10 days
Study NCT01049438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral anti-MRSA antibiotic
Description: The choice of oral antibiotic was based on investigators choice and antibiotic susceptibility of prior MRSA isolates in a given patient
Study NCT04192110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diuretic initiation or augmentation
Description: The participant's blood pressure medication regimen will then be altered to initiate a thiazide-type (hydrochlorothiazide or chlorthalidone) or loop diuretic (furosemide, bumetanide, or torsemide) in those not already prescribed a diuretic, or to increase the dose if one is already prescribed
Study NCT02019186 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: \<30 kg 250 mg 30-60 kg 500 mg >60 kg 750 mg
Study NCT02019186 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: \<30 kg 100 IU, 30-60 kg 200 IU, >60 kg 300 IU
Study NCT05256615 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 30-minute walking intervention
Description: Participants are asked to go for a 30 minute walk once per day at any time except the 1 hour after a meal. During these walks they are asked to record heart rate using a heart rate monitor and a phone application.
Study NCT05256615 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10-minute
Description: Participants are asked to go for a 10-minute walk after each meal occurring 3 times daily. During these walks they are asked to record heart rate using a heart rate monitor and a phone application.
Study NCT03119545 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beardslee family centered intervention
Description: The method entails six meetings. The time for the meeting is 1-2 hours and is usually held once per week. Meetings 1 and 2) include only the parents and focus firstly on the ill parent's history and secondly on the well parent/relative. Meeting 3) includes interviews with each child aged 6-19 years, without the parents being present, concerning the child´s understanding of the disease, potential worries and questions. During the interview the child can formulate his or her own questions for the family meeting. Meeting 4) includes the parents and focuses on the planning of the family meeting. The child's thoughts and questions serve as a guide for the upcoming family meeting. Meeting 5) is the family meeting. Meeting 6) is a follow-up with all of the family members.
Study NCT03909737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo to infants
Description: Placebo to infants at 6 and 14 week EPI visits
Study NCT03909737 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to infants
Description: Placebo to infants at 6 and 14 week EPI visits
Study NCT03909737 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention to pregnant women
Description: No intervention to pregnant women
Study NCT03909737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention to pregnant women
Description: No intervention to pregnant women
Study NCT05529888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin
Description: Isotretinoin is a vitamin-A derivative for treatment of moderate to severe acne used in a dose from 20-40 mg for 3 months duration
Study NCT02108769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yogic Breathing
Description: 1. Chanting Om~   1. Sharp deep inhalation through nostrils~  2. Slow exhalation through mouth while chanting Om. At this step the subjects will perform a slow and complete exhalation.~   Repeat for 10 min. During the whole period of chanting, the subjects keep their eyes closed.~2. Yogic Breathing:~   1. Check which of the two nostrils exhibit free flow of air. For the explanation purpose the nostril with free flow of air is treated as Nostril 1 and the other one as Nostril 2.~  2. Close Nostril 2 and inhale a sharp deep breath through Nostril 1 and then close both the nostrils so no inhaled air escapes. Air should not escape through mouth either. This inhalation step should take about 4 seconds.~  3. Hold breath in this position for about 16 seconds.~  4. Open Nostril 2 and exhale for about 8 seconds. Complete exhalation is required. Abdomen will slowly curve-in as the subject exhales. This is normal and encouraged. No air should leak through the Nostril 1 or mouth.~  5. Go to step a).
Study NCT01882803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: Phosphoinositide-3-kinase (PI3K) inhibitor
Study NCT03270033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 0.4 millilitres (mL) of 10 milligram per mL sterile, preservative free solution diluted in 50 or 100mL of normal saline and administered once, over approximately 15 minutes, in the immediate preoperative period.
Study NCT03270033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 0.5 millilitres (mL) of 100 microgram per mL sterile, preservative free solution diluted in 50 or 100mL of normal saline and administered once, over approximately 15 minutes, in the immediate preoperative period.
Study NCT04388124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: vascular assesment Clinical exam urinary analysis blood results natriuresis and measured glomerular filtration rate
Study NCT04388124 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03445403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Offset analgesia
Description: Exposure to a moderate heat-pain stimulus applied for 5 seconds, raised by 1 degree C for 5 seconds, reduced by 1 degree C, and held for 20 seconds using a computerized paradigm in order to evoke endogenous pain modulation.
Study NCT03445403 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Offset analgesia
Description: Exposure to a moderate heat-pain stimulus applied for 5 seconds, raised by 1 degree C for 5 seconds, reduced by 1 degree C, and held for 20 seconds using a computerized paradigm in order to evoke endogenous pain modulation.
Study NCT03743025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide Injection
Description: Participants randomized at pre-surgery/anesthesia visit and without a history of DM will receive a single injection of Dulaglutide injection: 0.75 mg/0.5 mL solution in a single-dose pen 1 to 3 days prior to surgery
Study NCT03743025 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Injection
Description: Participants randomized at pre-surgery/anesthesia visit and without a history of DM will receive a single injection of Saline injection/0.5 mL pre-drawn solution 1 to 3 days prior to surgery
Study NCT04095325 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided erector spinae block
Description: Group 2 (n: 50): those who underwent ESP block after propofol atropine induction and maintained with only 1 mg / kg / h propofol in anesthesia maintenance
Study NCT03672344 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lookware TM
Description: Lookware TM is a computer-based video game that requires the subject engage in social skills related exercises that include certain visual behaviors. These exercises combine techniques from applied behavior analysis (ABA) and use of gaze-contingent eye tracking technology during simulated social interactions with 3D animated characters to target certain social skills deficits in children with autism spectrum disorder (ASD). The game is delivered through a laptop computer, eye tracker, and game controller.
Study NCT03672344 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Lookware TM Control Module
Description: Lookware TM Control Module is a version of the Lookware TM computer-based video game that excludes the social skills related exercises. The game is delivered through a laptop computer, eye tracker, and game controller.
Study NCT01014078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Ophthalmic Solution, 1%
Description: 1 drop BID for the first 2 days and then 1 drop once a day for the remainder of the study (29 ± 1 days)
Study NCT01014078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 drop BID for the first 2 days and then 1 drop once a day for the remainder of the study (29 ± 1 days)
Study NCT02108769 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: The participants will read a text of their choice for 20 minutes in a one-on-one session with the Yoga Instructor.
Study NCT05133492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular Aneurysm Stabilization Treatment (EAST)
Description: Endovascular procedure: an ipsilateral ilio-femoral aortogram to confirm suitability for placement of a 14F sheath will be performed. A baseline contrast aortogram will be performed to assess vessel patency and target location of the EAST delivery catheter. Occluding and Stabilizer balloons are inflated in preparation for Stabilizer Compound delivery within the AAA sac. A post-Stabilizer angiogram will re-assess vessel patency and aorta stability. Delivery catheter is removed and discarded. The entire procedure is approximately one hour.
Study NCT02875197 — intervention group
Intervention type: OTHER
Intervention: Running on a treadmill at 6 different speeds
Description: All subjects will be required to run at 6 prescribed speeds (2.5, 3.0, 3.5, 4.0, 5.0, and 6.0 m/sec) on a treadmill completing at least 10 consecutive strides, or running for 30 seconds.
Study NCT04537533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Intraoperative infusion
Study NCT04537533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: Intraoperative infusion
Study NCT04537533 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: intravenous infusion
Study NCT04537533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: intravenous infusion
Study NCT04537533 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: intravenous infusion
Study NCT04544059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide orally 25 mg per day was administered on days 1 through 10 of each cycle and delivered concomitantly with standard dose R-CHOP-21 regimen (rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2 or Liposome doxorubicin 30mg/m2, vincristine 1.4 mg/m2 \[capped at 2.0 mg\], all on day 1; prednisone 100 mg per day on days 1 through 5). All patients received aspirin 100mg per day prophylaxis throughout, unless they were on therapeutic dose warfarin or low molecular weight heparin for intercurrent conditions. The treatment continued for a maximum of six to eight cycles or until disease progression. Tumor lysis prophylaxis, antiemetics, and supportive care were standard of care.
Study NCT02105285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-1085EL ophthalmic solution
Study NCT02105285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carteolol long-acting ophthalmic solution
Study NCT04110899 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of paratracheal force
Description: An esophageal stethoscope is inserted into the upper esophagus under the application of different paratracheal force in anesthetized and paralyzed patients.
Study NCT03724045 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Back Side of the Moon
Description: The procedures are: several measurements will be performed, including some which are not part of the Standard Operating Procedure, hence causing it to be considered interventional.~Follow-up during consultation on pneumology until max. 6 months post-admission on the ICU.
Study NCT02122315 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy plus dry needling
Description: Best-evidence physical therapy intervention in addition to a single session of TrP-DN targeted to active TrPs in the neck-shoulder muscles
Study NCT02122315 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: Best-evidence physical therapy intervention
Study NCT02681458 — intervention group
Intervention type: OTHER
Intervention: Direct Examination
Description: It was an observational study and subjects received their routine treatment.
Study NCT01808261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK249320 100/mg
Description: Clear to opalescent, colorless to pale yellow or pale brown, and is supplied as a sterile, concentrated solution (1000mg/vial). GSK249320 is for IV use only.
Study NCT01808261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a clear, colorless solution (50mM acetate buffer, pH 5.5 containing 0.02% (w/v) polysorbate-80 and made isotonic with 111.2 mM sodium chloride). Placebo is for intravenous (IV) use only.
Study NCT05620615 — intervention group
Intervention type: OTHER
Intervention: Intensive Drug Therapy
Description: Observational only and no predesigned interventions in this study
Study NCT03026959 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: The mindfulness intervention follows the structure described by Short, Mazmanian, Ozen, \& Bédard, (2015).
Study NCT00287729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirfenidone
Description: 2403 mg/day given orally, and administered in divided doses three times daily with food, for the duration of the study.
Study NCT00287729 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo equivalent, given orally, and administered in divided doses three times daily with food, for the duration of the study.
Study NCT05437445 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma amino acid assay
Description: Plasma amino acid analysis was performed on all the blood samples received in biogenetics lab at Aga khan university, Karachi during one year period.
Study NCT00665483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin Prick Test
Description: Skin Prick Test
Study NCT02916134 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic +/- Open Appendicectomy
Description: Laparoscopic +/- open appendicectomy , with antibiotics at induction (intravenous co-amoxiclav 1.2g, or if penicillin allergic, cefuroxime 1.5g + metronidazole 500mg ), followed by 3 further intravenous doses of the same antibiotic. If a perforation is identified at the time of surgery, microbiology will be contacted regarding choice and duration of of antibiotic.
Study NCT00806481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer carbonate
Description: Treatment group: treatment with 1600mg tablets of sevelamer carbonate three times daily for 36 weeks
Study NCT00806481 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment group: treatment with tablets of placebo three times daily for 36 weeks
Study NCT02916134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Description: Intravenous co-amoxiclav 1.2g three times daily, then 625mg, orally three times daily. If penicillin allergic, intravenous cefuroxime 1.5g three times daily + metronidazole 500mg three times daily, then oral cefuroxime 500mg twice daily + oral metronidazole 400mg three times daily.~The patient will receive inpatient intravenous antibiotics until sufficient clinical improvement is noted by the surgical team, who will be assessing the patient twice daily. After discharge the patient will receive 5 further days of oral antibiotics.
Study NCT01537380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazoline
Description: Injection of CEFAZOLINE (4 grams) 30-60 min before skin incision. A second injection will performed every 4 hours during the surgery
Study NCT02728817 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: End-cephalic vein to side-radial artery fistula creation
Description: * Circumferential dissection of the cephalic vein (4-5cm long)~* Longitudinal arteriotomy (\~10mm)~* End-vein to side-artery anastomosis using 7-0 polypropylene continuous suture
Study NCT02728817 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RADAR fistula creation
Description: * Dissection of the anterior-medial aspect of the cephalic vein (\~15mm) without grasping or clamping the venous wall~* Circumferential dissection of the radial artery pedicle (5cm long) and ligation of collaterals with surgical microclips~* Ligation and section of the radial artery (distal)~* Longitudinal venotomy (\~10mm)~* End-artery to side-vein anastomosis using 7-0 polypropylene continuous suture
Study NCT02450838 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V180
Description: Tetravalent recombinant subunit dengue vaccine; V180 will contain 10 µg, 10 µg, 10 µg, and 20 µg of the DENV1, DENV2, DENV3, and DENV4 antigens, respectively.
Study NCT02450838 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alhydrogel™
Description: Aluminum hydroxide gel adjuvant
Study NCT02450838 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04319926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine topical system 1.8%
Description: One topical system is applied to the subject's back for 12 hours.
Study NCT04319926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine patch 5%
Description: One generic lidocaine patch is applied to the subject's back for 12 hours.
Study NCT02532283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872
Description: Participants will be administered JNJ-63623872 600 milligram (mg) tablets orally twice daily for 7 days.
Study NCT02532283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will be administered placebo tablets orally twice daily for 7 days.
Study NCT04553055 — intervention group
Intervention type: OTHER
Intervention: online questionnaires
Description: questionnaire (with detailed questions including how/when/which/for how long antibiotics are prescribed)
Study NCT01217788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH94B intranasal spray
Description: Comparison of PH94B single dose intranasal spray and Placebo single dose intranasal spray
Study NCT01217788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PH94B intranasal spray
Description: Comparison of PH94B single dose intranasal spray and Placebo single dose intranasal spray
Study NCT01835353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel 100mg loading dose
Study NCT01835353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel 60mg loading dose
Description: Prasugrel 60mg loading dose
Study NCT03388476 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Capnography
Description: Measuring of the exhaled air, especially endtidal co2, through capnography.
Study NCT02878603 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Caplacizumab
Study NCT02878603 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: • PE with plasma (e.g., fresh frozen plasma, solvent detergent/viral-inactivated plasma, cryosupernatant), • Corticosteroid treatment and • Use of other immunosuppressive agents (e.g., rituximab).
Study NCT03965715 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D printing AFO, anterior AFO, off-the-shelf AFO
Description: Subjects wear different AFOs and performed gait analysis.
Study NCT03180567 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Genetic Mutations
Description: By next generation sequencing
Study NCT03180567 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Genetic Mutations
Description: By next generation sequencing
Study NCT02373579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 Fatty Acids
Description: study group, included standard risk ALL pediatric patients who were supplemented with oral omega-3 capsule (one capsule / day) .~Omega-3 was supplied as soft gelatin capsules in a dose of 1000 mg of omega-3 fatty acids/day .
Study NCT02373579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: control group, included pediatric patients with standard risk acute lymphoblastic leukemia in maintenance phase day 0 and receiving oral Methotrexate (20 mg / m2) weekly without any supplementation .
Study NCT02895932 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET imaging
Description: Serotonin, Dopamine and Amyloid PET imaging
Study NCT04513639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early treatment of relapse with carfilzomib, dexamethasone, daratumumab
Description: Second line treatment will start at MRD reapperance
Study NCT04513639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment of relapse with carfilzomib, dexamethasone, daratumumab
Description: Second line treatment will start at progressive disease